What is the appropriate treatment for enterocolitis?

Treatment for Enterocolitis

The treatment of enterocolitis depends critically on the underlying etiology, but for immune checkpoint inhibitor (ICI)-related enterocolitis—the most comprehensively addressed form in current guidelines—systemic glucocorticoids at 0.5-2 mg/kg prednisone equivalent daily represent first-line therapy, with infliximab or vedolizumab reserved for glucocorticoid-refractory cases. 1

Initial Assessment and Diagnostic Workup

Before initiating treatment, you must establish the specific type of enterocolitis:

• Rule out infectious causes first: Test all patients for Clostridioides difficile and perform stool cultures or pathogen panels 1
• Check stool inflammatory markers: Fecal lactoferrin or calprotectin (90% sensitivity for histologic inflammation) helps stratify patients and determine need for endoscopy 1
• Consider endoscopy early: Flexible sigmoidoscopy or colonoscopy with biopsies is the reference standard for ICI enterocolitis and predicts treatment response—endoscopic findings (particularly colonic ulceration) are more predictive than symptoms alone 1

Treatment Algorithm by Etiology

ICI-Related Enterocolitis (Most Rigorously Studied)

Grade 1-2 (Mild):

• Continue ICI therapy with supportive care
• Consider anti-diarrheal agents
• For microscopic colitis variant: mesalamine or budesonide 1

Grade 2-3 (Moderate):

• Withhold ICI therapy
• Systemic glucocorticoids: 0.5-2 mg/kg prednisone equivalent daily (oral or IV) with 4-6 week taper 1
• If no response within 72 hours or incomplete response within 1 week, escalate to second-line therapy

Glucocorticoid-Refractory Disease:

• Infliximab 5 mg/kg IV at weeks 0,2, and 6, OR
• Vedolizumab 300 mg IV at weeks 0,2, and 6 1
• Response typically occurs within 1 week (faster than in IBD)
• Choose infliximab over vedolizumab EXCEPT in: hematologic malignancies (lymphoma risk), severe heart failure, or concurrent ICI hepatitis 1

Severe/Complicated:

• IV glucocorticoids immediately
• Early surgical consultation for perforation (occurs in 1%-6.6%), toxic megacolon, or uncontrolled bleeding 2

Neutropenic Enterocolitis

Conservative management is primary 3, 4, 5:

• Bowel rest with nasogastric decompression
• IV fluids and electrolyte replacement
• Total parenteral nutrition
• Broad-spectrum antibiotics covering gram-negative and anaerobic organisms
• Normalize neutrophil counts (G-CSF if appropriate)

Surgical intervention indicated for 4, 5:

• Free intraabdominal air (perforation)
• Intestinal obstruction
• Persistent GI bleeding despite correction of cytopenias
• Clinical deterioration suggesting uncontrolled sepsis

C. difficile Enterocolitis

• Vancomycin or metronidazole as first-line antibiotics 6
• Discontinue predisposing antibiotics when possible
• Total colectomy reserved for fulminant cases 6

Bacterial Enterocolitis (Non-C. difficile)

• Many cases resolve with oral rehydration alone 7
• Antibiotics indicated for severe diarrhea or extraintestinal symptoms 7
• Specific antibiotic choice depends on identified pathogen

Critical Pitfalls to Avoid

1. Don't delay endoscopy in ICI enterocolitis: Early endoscopy correlates with improved outcomes, and deep ulcerations predict steroid-refractory disease 2, 1

2. Don't miss the 40% with normal mucosa: Despite grade 2 symptoms, 40% of ICI enterocolitis patients have normal-appearing colon—biopsies are essential 2

3. Don't assume neutropenic enterocolitis without autopsy/surgical confirmation: In one series, only 4 of 9 autopsied cases clinically diagnosed with neutropenic enterocolitis were confirmed; 4 had normal bowels 5

4. Don't use glucocorticoids longer than necessary: Evidence suggests systemic steroids may dampen antitumor responses in ICI patients 1

5. Screen for latent infections before biologics: Test for hepatitis B, tuberculosis, HIV, and hepatitis C before initiating infliximab or vedolizumab 1

Special Considerations

Upper GI involvement in ICI enterocolitis (50%-75% have histologic inflammation) often responds to proton-pump inhibitors alone; severe gastric ulcerations may require steroids or biologics 2

Pancreatic insufficiency is an uncommon cause of diarrhea in ICI patients—check fecal elastase in non-responders or those with steatorrhea 1

Timing matters: Anti-CTLA-4 enterocolitis develops earlier (median 1 month) than anti-PD-1 (2-4 months), with maximum delays of 2 months and 1 year post-discontinuation, respectively 2